Adam Farag, Cornel Felder, Douglas Hussey, Seyed Ali Mirshahvalad, Sara Harsini, Ur Metser, Patrick Veit-Haibach
{"title":"Effect of data-driven gating on the quantification of prostate cancer metastases in <sup>68</sup>Ga-PSMA- and ¹⁸F-DCFPyL-PSMA PET/CT.","authors":"Adam Farag, Cornel Felder, Douglas Hussey, Seyed Ali Mirshahvalad, Sara Harsini, Ur Metser, Patrick Veit-Haibach","doi":"10.1186/s41824-026-00328-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>PSMA PET/CT using <sup>18</sup>F‑DCFPyL and <sup>68</sup>Ga‑labelled tracers is central to prostate cancer staging, but <sup>68</sup>Ga‑PSMA may show reduced sensitivity and quantitative accuracy, partly due to respiratory motion and lower spatial resolution. Device-based motion‑correction methods have limitations. Data‑driven gating (DDG) offers a hardware‑free alternative, though its impact on PSMA PET, especially <sup>68</sup>Ga‑PSMA has not been systematically evaluated. To evaluate the quantitative and qualitative performance of the DDG motion-correction method in <sup>68</sup>Ga-PSMA and <sup>18</sup>F-DCFPyL-PSMA PET/CT, focusing on metastatic lymph node, lung, and bone lesions, and to assess its robustness across tracers.</p><p><strong>Methods: </strong>This retrospective study included patients with biopsy‑proven prostate cancer who underwent <sup>68</sup>Ga‑PSMA or <sup>18</sup>F‑DCFPyL PSMA PET/CT for primary staging or biochemical recurrence and had metastatic disease. Motion correction was applied using the OncoFreeze AI™ data‑driven gating (OFAI‑DDG) method. Metastatic lesions were segmented semi‑automatically, and SUV metrics, image noise, and contrast‑to‑noise ratio were quantified by anatomical site in both OFAI-DDG and static images. Qualitative image quality was independently scored by two experienced readers. Statistical analyses included non‑parametric tests, Bland-Altman agreement, regression analyses, tracer comparison, and inter‑reader reliability assessment.</p><p><strong>Results: </strong>After exclusions, 23 <sup>68</sup>Ga‑PSMA and 40 <sup>18</sup>F‑PSMA patients were analyzed, yielding 133 and 192 metastatic lesions, respectively. OFAI‑DDG reconstruction significantly increased SUV<sub>mean</sub> and SUV<sub>max</sub> compared with static imaging for both tracers across bone, lymph node, and lung lesions (p < 0.0001), with the largest gains in lung lesions. CNR improved for most lesion types, and image noise was significantly reduced. Qualitative analysis showed better image quality, sharpness, and noise with OFAI‑DDG, with high inter‑reader agreement. OFAI‑DDG performance was robust across tracers and largely independent of lesion location.</p><p><strong>Conclusions: </strong>This study demonstrates that OFAI‑DDG significantly improves PSMA PET/CT image quality and quantitative accuracy compared with standard static imaging. The improvements were observed for both <sup>68</sup>Ga‑PSMA and <sup>18</sup>F‑PSMA tracers, indicating tracer‑independent robustness. The OFAI‑DDG simplified the workflow and reduced time used for patient set-up, while enhancing lesion visualization and quantitative reliability without altering lesion detection, supporting its clinical value for metastatic prostate cancer imaging.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"10 1","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41824-026-00328-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: PSMA PET/CT using 18F‑DCFPyL and 68Ga‑labelled tracers is central to prostate cancer staging, but 68Ga‑PSMA may show reduced sensitivity and quantitative accuracy, partly due to respiratory motion and lower spatial resolution. Device-based motion‑correction methods have limitations. Data‑driven gating (DDG) offers a hardware‑free alternative, though its impact on PSMA PET, especially 68Ga‑PSMA has not been systematically evaluated. To evaluate the quantitative and qualitative performance of the DDG motion-correction method in 68Ga-PSMA and 18F-DCFPyL-PSMA PET/CT, focusing on metastatic lymph node, lung, and bone lesions, and to assess its robustness across tracers.
Methods: This retrospective study included patients with biopsy‑proven prostate cancer who underwent 68Ga‑PSMA or 18F‑DCFPyL PSMA PET/CT for primary staging or biochemical recurrence and had metastatic disease. Motion correction was applied using the OncoFreeze AI™ data‑driven gating (OFAI‑DDG) method. Metastatic lesions were segmented semi‑automatically, and SUV metrics, image noise, and contrast‑to‑noise ratio were quantified by anatomical site in both OFAI-DDG and static images. Qualitative image quality was independently scored by two experienced readers. Statistical analyses included non‑parametric tests, Bland-Altman agreement, regression analyses, tracer comparison, and inter‑reader reliability assessment.
Results: After exclusions, 23 68Ga‑PSMA and 40 18F‑PSMA patients were analyzed, yielding 133 and 192 metastatic lesions, respectively. OFAI‑DDG reconstruction significantly increased SUVmean and SUVmax compared with static imaging for both tracers across bone, lymph node, and lung lesions (p < 0.0001), with the largest gains in lung lesions. CNR improved for most lesion types, and image noise was significantly reduced. Qualitative analysis showed better image quality, sharpness, and noise with OFAI‑DDG, with high inter‑reader agreement. OFAI‑DDG performance was robust across tracers and largely independent of lesion location.
Conclusions: This study demonstrates that OFAI‑DDG significantly improves PSMA PET/CT image quality and quantitative accuracy compared with standard static imaging. The improvements were observed for both 68Ga‑PSMA and 18F‑PSMA tracers, indicating tracer‑independent robustness. The OFAI‑DDG simplified the workflow and reduced time used for patient set-up, while enhancing lesion visualization and quantitative reliability without altering lesion detection, supporting its clinical value for metastatic prostate cancer imaging.